scholarly journals Hyperkinetic Dysarthria with Spasmodic Torticollis

2020 ◽  
Vol 28 (2) ◽  
pp. 177-181
Author(s):  
Susmi Pani ◽  
Shruti Kabra ◽  
Shilpi Chakraborty ◽  
Indranil Chatterjee
Keyword(s):  
Botulinum Toxin ◽  
Treatment Efficacy ◽  
Speech Therapy ◽  
Communicative Competence ◽  
Spasmodic Torticollis ◽  
Unknown Etiology ◽  
Speech Characteristics ◽  
The Right ◽  
Post Therapy

Introduction   Spasmodic Torticollis is a condition in which tonic or clonic spasm in the Sternocleidomastoid and Trapezius muscles, cause the head to be deviated to the right or left and has also been reported to disrupt speech production. Spasmodic Torticollis is a part of unknown etiology of Hyperkinetic Dysarthria. Case Report   We report a case of 30 years old male diagnosed as Hyperkinetic Dysarthria who was treated with speech therapy and without Botulinum toxin. Post therapy status was recorded after 12 sessions (frequency twice a week) and it shows improvement in speech characteristics. Discussion   Management of the patients with Hyperkinetic Dysarthria with Spasmodic Torticollis is a long term and often a lifelong process. Speech therapy is offered at intervals in order to maintain communicative competence. Reported studies suggest the use of Botulinum toxin, but in the present study treatment efficacy was proven without the use of Botulinum toxin.

scholarly journals A Pilot Study on the Use of Botulinum Toxin in Spasmodic Torticollis

1985 ◽  
Vol 12 (4) ◽  
pp. 314-316 ◽  
Author(s):  
J.K. Tsui ◽  
A. Eisen ◽  
E. Mak ◽  
J. Carruthers ◽  
A. Scott ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Pilot Study ◽  
Spasmodic Torticollis ◽  
Blind Study ◽  
Long Term Effects ◽  
Optimum Dosage ◽  
Abnormal Movements ◽  
Local Injections ◽  
Single Blind

ABSTRACT:Dystonic torticollis has been treated with local injections of botulinum toxin in a single blind study of 12 patients. A significant decrease of abnormal movements was recorded, and pain improved. Further studies are desirable to define the optimum dosage and site for injections, and the long term effects of repeated injections.

Treatment of spasticity of different origins with botulinum toxin A: long-term results

2008 ◽  
Vol 35 (S 01) ◽  
Author(s):  
K Kollewe ◽  
S Baloush ◽  
K Krampfl ◽  
H Bigalke ◽  
R Dengler ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Long Term Results ◽  
Toxin A ◽  
Different Origins

Corticosteroids in Inflammatory Bowel Disease patients: a practical guide for physicians.

2020 ◽  
Vol 15 ◽  
Author(s):  
Maria Carla Di Paolo ◽  
Cristiano Pagnini ◽  
Maria Giovanna Graziani
Keyword(s):  
Severe Disease ◽  
Unknown Etiology ◽  
History Of Disease ◽  
Bowel Diseases ◽  
Literature Evidence ◽  
History Of ◽  
Inflammatory Bowel ◽  
Favorable Safety ◽  
Pass Metabolism

: Inflammatory bowel diseases (IBDs) are chronic conditions characterized by unknown etiology and pathogenesis with deregulation of mucosal immunity. Among possible treatments, corticosteroids, already available from the 50’, are still the mainstay of treatment for moderate-severe disease. Nonetheless, the use of steroids is still largely empirical and solid evidence about therapeutic schemes are lacking. Moreover, due to the important side-effects and for the unsatisfactory impact on long-term natural history of disease, the steroid sparing has become an important therapeutic goal in IBD management. Besides conventional steroids, the so called “low bioavailability” steroids, which are steroids with high affinity for peripheral receptors and elevated hepatic first-pass metabolism, have demonstrated efficacy and more favorable safety profile. In the present review of the literature evidence of efficacy and safety of conventional and low bioavailability steroids in IBD patients are evaluated, and practical suggestions for a correct use in clinical practice are presented according to the current clinical guidelines.

scholarly journals Clinical Study of 107 Hospitalized Patients with Peritonsillar Abscess

2021 ◽  
Vol 04 (01) ◽  
pp. e11-e16
Author(s):  
Risa Wakisaka ◽  
Takumi Kumai ◽  
Kan Kishibe ◽  
Miki Takahara ◽  
Akihiro Katada ◽  
...  
Keyword(s):  
Clinical Study ◽  
Initial Treatment ◽  
Peritonsillar Abscess ◽  
Laryngeal Edema ◽  
Antibacterial Drugs ◽  
Inferior Pole ◽  
Duration Of Hospitalization ◽  
The Right ◽  
Superior Pole

AbstractWe conducted a retrospective analysis of the data of 107 cases of peritonsillar abscess treated at our hospital between January 2014 and December 2018. Data on age, sex, affected site, duration of hospitalization, method of drainage, presence/absence of laryngeal edema, antibacterial drugs used, and isolated bacteria were analyzed. Of the 107 patients, 71 were males and 36 were females; the median age was 44 years (range: 18–88 years).The left side was affected in 55 patients, the right side in 50 patients, and both sides in two patients. The abscess was localized in the superior pole in 71 patients, and in the inferior pole in 36 patients. Thirty-five patients had laryngeal edema, of which three underwent tracheotomy. Recurrence of the abscess was observed in 15 cases, with the recurrence developing within 3 months in 7 cases, and over a period of 3 years in 4 cases. As for the sensitivity of the causative bacteria to antibacterial drugs, 17% of the causative bacteria showed resistance to clindamycin, while none showed resistance to ampicillin/sulbactam (ABPC/SBT). We concluded that ABPC/SBT might be suitable for the initial treatment of peritonsillar abscess, and that we need to bear in mind the possibility of long-term recurrence.

Physiological Pacing: A New Road to Future

2021 ◽  
pp. 263246362097804
Author(s):  
Vanita Arora ◽  
Pawan Suri
Keyword(s):  
Side Effects ◽  
Fibrous Tissue ◽  
Cardiac Pacing ◽  
His Bundle ◽  
Anatomy And Physiology ◽  
Long Term Follow Up ◽  
Pacing Lead ◽  
The Right

Anatomy and physiology are the basis of human body functioning and as we have progressed in management of various diseases, we have understood that physiological intervention is always better than an anatomical one. For more than 50 years, a standard approach to permanent cardiac pacing has been an anatomical placement of transvenous pacing lead at the right ventricular apex with a proven benefit of restoring the rhythm. However, the resultant ventricular dyssynchrony on the long-term follow-up in patients requiring more than 40% ventricular pacing led to untoward side effects in the form of heart failure and arrhythmias. To counter such adverse side effects, a need for physiological cardiac pacing wherein the electrical impulse be transmitted directly through the normal conduction system was sought. His bundle pacing (HBP) with an intriguing alternative of left bundle branch pacing (LBBP) is aimed at restoring such physiological activation of ventricles. HBP is safe, efficacious, and feasible; however, localization and placement of a pacing lead at the His bundle is challenging with existing transvenous systems due to its small anatomic size, surrounding fibrous tissue, long-learning curve, and the concern remains about lead dislodgement and progressive electrical block distal to the HBP lead. In this article, we aim to take the reader through the challenging journey of HBP with focus upon the hardware and technique, selective versus nonselective HBP, indications and potential disadvantages, and finally the future prospects.

Sign in / Sign up

Export Citation Format

Share Document